VAXXITEK HVT + IBD

serotype 3, live Marek’s disease vector, live vHVT013-69 recombinant virus (and diluent)

About VAXXITEK® HVT + IBD

To prevent mortality and to reduce clinical signs and lesions of infectious bursal disease. The onset of protection is two weeks and the protection extends to nine weeks.

To reduce mortality, clinical signs and lesions of Marek’s disease. The onset of protection is four days. A single vaccination is sufficient to provide protection during the risk period.

 

Product Key Facts

Indications

Infectious bursal disease and Marek’s disease

Brand names

VAXXITEK® HVT + IBD

Active ingredients

serotype 3, live Marek’s disease vector, live vHVT013-69 recombinant virus (and diluent)